{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:12:53Z","timestamp":1787026373523,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2017.00254","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T05:05:40Z","timestamp":1506575140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response"],"prefix":"10.3389","volume":"8","author":[{"given":"Mario","family":"Rotondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Molteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Leporati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Capelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Chiovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrneurol.2013.2","article-title":"Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS","volume":"9","author":"Wiendl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.autrev.2016.03.006","article-title":"Therapeutic strategies targeting B-cells in multiple sclerosis","volume":"15","author":"Milo","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.expneurol.2014.04.018","article-title":"Mode of action and clinical studies with alemtuzumab","volume":"262","author":"Jones","year":"2014","journal-title":"Exp Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.beem.2009.07.003","article-title":"Immune reconstitution syndrome and the thyroid","volume":"23","author":"Weetman","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jamaneurol.2017.0325","article-title":"Induction of new autoimmune diseases after alemtuzumab therapy for multiple sclerosis learning from adversity","volume":"74","author":"Steinman","year":"2017","journal-title":"JAMA Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jneuroim.2011.01.013","article-title":"Interferon-\u03b2 but not glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs","volume":"234","author":"Rotondi","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","article-title":"Alemtuzumab more effective than interferon \u03b2-1a at 5-year follow-up of CAMMS223 clinical trial","volume":"78","author":"Coles","year":"2012","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/cen.12427","article-title":"Graves\u2019 disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?","volume":"80","author":"Weetman","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B15","unstructured":"Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis2017"},{"key":"B16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0165-5728(03)00154-1","article-title":"Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta","volume":"139","author":"Batocchi","year":"2003","journal-title":"J Neuroimmunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04143.x","article-title":"T cells in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"162","author":"Fletcher","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0022-510X(01)00637-2","article-title":"Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study","volume":"193","author":"Durelli","year":"2001","journal-title":"J Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.msard.2012.06.001","article-title":"The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: a population-based study","volume":"1","author":"Marrie","year":"2012","journal-title":"Mult Scler Relat Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s00415-003-1053-9","article-title":"Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis","volume":"250","author":"Niederwieser","year":"2003","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1740-2557-2-9","article-title":"Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort","volume":"2","author":"Sloka","year":"2005","journal-title":"J Autoimmune Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/brain\/123.6.1102","article-title":"Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey","volume":"123","author":"Broadley","year":"2000","journal-title":"Brain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1089\/105072502320908312","article-title":"Disease associations with autoimmune thyroid disease","volume":"12","author":"Jenkins","year":"2002","journal-title":"Thyroid"},{"key":"B24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2265.2010.03855.x","article-title":"Diseases associated with thyroid autoimmunity: explanations for the expanding spectrum","volume":"74","author":"Weetman","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/jc.2004-2326","article-title":"Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration","volume":"90","author":"Caraccio","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1410325","article-title":"Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis","volume":"141","author":"Monzani","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/BF03348040","article-title":"Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis","volume":"21","author":"Rotondi","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/1352458514533387","article-title":"Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-\u03b2 and glatiramer acetate?","volume":"20","author":"Rotondi","year":"2014","journal-title":"Mult Scler"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1177\/1352458514521311","article-title":"Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study","volume":"20","author":"Frisullo","year":"2014","journal-title":"Mult Scler"},{"key":"B30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3413\/Nukmed-0739-15-04","article-title":"Etiopathogenesis of Basedow\u2019s disease. Trends and current aspects","volume":"54","author":"Leporati","year":"2015","journal-title":"Nuklearmedizin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40618-014-0214-2","article-title":"Role of genetic and non-genetic factors in the etiology of Graves\u2019 disease","volume":"38","author":"Marin\u00f2","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40618-016-0505-x","article-title":"Management of hyperthyroidism due to Graves\u2019 disease: frequently asked questions and answers (if any)","volume":"39","author":"Bartalena","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1210\/jcem.83.3.4676","article-title":"Thyrotropin receptor expression in Graves\u2019 orbital adipose\/connective tissues: potential autoantigen in Graves\u2019 ophthalmopathy","volume":"83","author":"Bahn","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1055\/s-0035-1559633","article-title":"Graves\u2019 disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies","volume":"47","author":"Morshed","year":"2015","journal-title":"Horm Metab Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fendo.2016.00120","article-title":"Thyrotropin receptor epitope and human leukocyte antigen in Graves\u2019 disease","volume":"7","author":"Inaba","year":"2016","journal-title":"Front Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1210\/jcem.83.1.4492","article-title":"Outcome of thyroid function in Graves\u2019 patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage","volume":"83","author":"Chiovato","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1210\/er.2006-0044","article-title":"Role of chemokines in endocrine autoimmune diseases","volume":"28","author":"Rotondi","year":"2007","journal-title":"Endocr Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.2174\/138161211798157559","article-title":"The chemokine system as a therapeutic target in autoimmune thyroid diseases: a focus on the interferon-\u03b3 inducible chemokines and their receptor","volume":"17","author":"Rotondi","year":"2011","journal-title":"Curr Pharm Des"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF03343730","article-title":"Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves\u2019 disease","volume":"23","author":"Rotondi","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI109601","article-title":"Hypothyroidism as a late sequela in patient with Graves\u2019 disease treated with antithyroid agents","volume":"64","author":"Wood","year":"1979","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3803\/EnM.2016.31.4.493","article-title":"Clinical update in aspects of the management of autoimmune thyroid diseases","volume":"31","author":"Topliss","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4049\/jimmunol.1000422","article-title":"A novel strategy to reduce the immunogenicity of biological therapies","volume":"185","author":"Somerfield","year":"2010","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"821","DOI":"10.4158\/EP13020.RA","article-title":"Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review","volume":"19","author":"Aranha","year":"2013","journal-title":"Endocr Pract"},{"key":"B48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.14310\/horm.2002.1501","article-title":"Graves\u2019 disease after treatment with alemtuzumab for multiple sclerosis","volume":"14","author":"Tsourdi","year":"2015","journal-title":"Hormones (Athens)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1017\/cjn.2015.48","article-title":"Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management","volume":"42","author":"Mahzari","year":"2015","journal-title":"Can J Neurol Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1177\/1352458516638558","article-title":"Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"22","author":"Obermann","year":"2016","journal-title":"Mult Scler"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/j.1600-6143.2006.01258.x","article-title":"Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab","volume":"6","author":"Kirk","year":"2006","journal-title":"Am J Transplant"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/pbc.25102","article-title":"Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease","volume":"61","author":"Williams","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/art.23122","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes","volume":"58","author":"Lorenzi","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2017.00254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T05:05:43Z","timestamp":1506575143000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2017.00254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,28]]},"references-count":54,"alternative-id":["10.3389\/fendo.2017.00254"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2017.00254","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,28]]},"article-number":"254"}}